|
Session 70
Poster Abstracts
Neuropathogenesis: Therapy and Clinical Studies
Wednesday, 1:30 - 3:30 pm
Poster Hall |
359
 |
NNRTI more than Boosted PI Exposure Enhances Virological Control in Cerebrospinal Fluid of HIV-1-infected Patients with Neurological Disorders
Maria Letizia Giancola*1, P Lorenzini1, A Cingolani2, D Larussa1, S Bossolasco3, M Bongiovanni4, L Monno5, A d'Arminio Monforte4, P Cinque3, A Antinori1, and Italian Registry Investigative Neuro AIDS Study Group
1Natl Inst for Infectious Diseases L Spallanzani IRCCS, Rome, Italy; 2Catholic Univ, Rome, Italy; 3San Raffaele Sci Inst, Vita e Salute Univ, Milan, Italy; 4Inst of Infectious and Tropical Diseases, L Sacco Hosp, Univ of Milan, Italy; and 5Univ of Bari, Italy |
| 360 |
Cerebrospinal Fluid HIV Infection in Relation to Systemic Infection and Treatment in Different Stages of HIV Disease
Gabriele Arendt*1, T Nolting1, C Frisch1, I W Husstedt2, E Koutsilieri3, M Maschke4, A Angerer4, S Sopper5, P Riederer3, V Ter Meulen3, and the Competence Network HIV/AIDS
1Univ of Duesseldorf, Germany; 2Univ of Muenster, Germany; 3Univ of Wuerzburg, Germany; 4Univ of Duisburg-Essen, Essen, Germany; and 5Georgetown Univ, Washington, DC, US |
361
|
ACTG 736: CSF HIV-1 and Cognitive Function in Individuals Receiving Potent ART
C Marra1, S Sinha2, S Evans2, S Letendre3, R Coombs1, F Aweeka4, D Clifford5, S Shriver6, X Li7, Kevin Robertson*8, and ACTG 736 Team
1Univ of Washington, Seattle, US; 2Statistical and Data Analysis Ctr, Harvard Sch of Publ Hlth, Boston, MA, US; 3Univ of California, San Diego, US; 4Univ of California, San Francisco, US; 5Washington Univ, St Louis, MO, US; 6ACTG, Washington, DC, US; 7Univ of California, Davis, Sacramento, US; and 8Univ of North Carolina at Chapel Hill, US |
| 362 |
Neurocognitive Impairment in HIV-infected Subjects on HAART: Prevalence and Associations
Kevin Robertson*1, K Wu2, T Parsons1, R Ellis3, M Smurzynski2, R Bosch2, J Wu2, J McArthur4, A Collier5, S Evans2, and the ACTG 5001 Protocol Team and the ACTG
1Univ of North Carolina at Chapel Hill, US; 2Harvard, Boston, MA, USA; 3Univ of California, San Diego, US; 4Johns Hopkins Univ, Baltimore, MD, US; and 5Univ of Washington, Seattle, US |
| 363 |
Cognitive Function and Adherence in Individuals Receiving ART: How You Think Changes What You Do
Kevin Robertson*, T Parsons, S Chauhan, J Liner, W Robertson, A Braaten, and C Hall
Univ of North Carolina at Chapel Hill, US |
| 364 |
A Phase II, Placebo-controlled, Double-blind Study of the Selegiline Transdermal System in the Treatment of HIV-associated Cognitive Impairment
Giovanni Schifitto*1, N Sacktor2, J Zhang3, S Evans3, D Simpson4, L Millar5, E Miller6, E Smith7, M Goodhead8, D Clifford9, and the ACTG A5090 Team
1Univ of Rochester Sch of Med and Dentistry, NY, US; 2Johns Hopkins Univ, Baltimore, MD, US; 3Harvard Sch of Publ Hlth, Boston, MA, US; 4Mt Sinai Sch of Med, New York, NY, US; 5Frontier Sci & Tech Res Fndn, Amherst, NY, US; 6David Geffen Sch of Med, Univ of California, Los Angeles Med Ctr, US; 7NIAID, NIH, DHHS, Bethesda, MD, US; 8Somerset Pharma, Tampa, FL, US; and 9Washington Univ, St Louis, MO, US |
| 365 |
Multi-drug Resistance-1 Gene and Indinavir Concentration in Cerebrospinal Fluid and Plasma from HIV-infected Individuals
J Marquie-Beck1, R Ellis1, M Buzzell1, Edmund Capparelli*1, S Rought1, J Corbeil1,2, D Holland1, S De Almeida1, S Letendre1, and the HNRC Group
1Univ of California, San Diego and 2Univ Laval, Quebec City, Canada |
366
|
Neurocognitive Impairment, Symptomatic Peripheral Neuropathy, and Depression in HIV-infected Outpatients within the Asia Pacific Region: Findings of the APNAC Study
Edwina Wright*1,2,3, B Brew4,5, L Lal2,3, D Imran6, W Lun7, A Kamarulzaman8, M Lim2, K Robertson9, J McArthur10, S Wesselingh1,2,3, and the APNAC Study Protocol Team
1Alfred Hosp, Melbourne, Australia; 2Burnet Inst, Melbourne, Australia; 3Monash Univ, Melbourne, Australia; 4St Vincent's Hosp, Sydney, Australia; 5Univ of New South Wales, Sydney, Australia; 6Univ of Indonesia, Jakarta; 7Ditan Hosp, Beijing, China; 8Univ Malaya, Kuala Lumpah; 9Univ of North Carolina at Chapel Hill, US; and 10Johns Hopkins Univ, Baltimore, MD, US |
| 367 |
Phase II Trial of Prosaposin-derived Peptides for HIV-associated Sensory Neuropathies: First Use of Electronic Diary to Record HIV-associated Neuropathic Pain
Scott Evans*1, D Simpson2, D Kitch1, D Clifford3, C Rehrig4, M Alton4, B Huang4, and J McArthur2
1Harvard Sch of Publ Hlth, Boston, MA, US; 2Johns Hopkins Univ, Baltimore, MD, US; 3Washington Univ, St Louis, MO, US; and 4Savient Pharma, East Brunswick, NJ, US |
| 368 |
Long-term Exposure to Dideoxynucleoside Analogues in the Treatment of HIV Infection Does not Result in Worsening Polyneuropathy Signs or Symptoms
Ronald Ellis*, S Letendre, J Lonergan, J Marquie-Beck, D Lazzaretto, C Hung, and the HIV Neurobehavioral Res Ctr Group
Univ of California, San Diego, La Jolla, US |
369
|
L-Acetyl Carnitine Prevents Antiretroviral Toxic Neuropathy in an in vitro Model
L Lal1, S Wesselingh1,2,3, G Tachedjian1, D Tyssen1, K Smyth1, J Glass4, and Catherine Cherry*1,2,3
1Burnet Inst, Melbourne, Australia; 2Alfred Hosp, Melbourne, Australia; 3Monash Univ, Melbourne, Australia; and 4Emory Univ, Atlanta, GA, US |
|
